Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $36,534.42 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,521 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $36,534.42. Following the sale, the chief financial officer owned 146,600 shares of the company’s stock, valued at approximately $3,521,332. This represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Stock Performance

Shares of CBLL traded up $0.01 during trading hours on Tuesday, hitting $23.95. The stock had a trading volume of 243,381 shares, compared to its average volume of 457,237. The firm has a market capitalization of $919.20 million, a PE ratio of -13.61 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33. The stock has a fifty day moving average price of $19.77 and a 200 day moving average price of $19.27.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

Institutional Investors Weigh In On CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System lifted its position in shares of CeriBell by 409.5% in the second quarter. California State Teachers Retirement System now owns 7,352 shares of the company’s stock valued at $143,000 after acquiring an additional 5,909 shares in the last quarter. Wellington Management Group LLP grew its position in shares of CeriBell by 5.5% during the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares in the last quarter. Formula Growth Ltd. bought a new stake in CeriBell during the 2nd quarter valued at approximately $603,000. Bank of America Corp DE bought a new stake in CeriBell during the 2nd quarter valued at approximately $4,619,000. Finally, PDT Partners LLC purchased a new position in CeriBell in the 2nd quarter worth approximately $1,026,000.

Analyst Ratings Changes

CBLL has been the topic of several analyst reports. Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. BTIG Research raised their price objective on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.